Compare SERA & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SERA | PYXS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 82.3M |
| IPO Year | 2021 | 2021 |
| Metric | SERA | PYXS |
|---|---|---|
| Price | $2.03 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 21.4K | ★ 361.8K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $13,858,000.00 |
| Revenue This Year | $554.81 | N/A |
| Revenue Next Year | $517.27 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $1.37 | $0.97 |
| 52 Week High | $4.09 | $5.55 |
| Indicator | SERA | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 57.12 |
| Support Level | $1.91 | $1.28 |
| Resistance Level | $2.41 | $2.17 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 26.72 | 63.39 |
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.